{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:14:24Z","timestamp":1784268864422,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12032-019-1309-6","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T15:02:52Z","timestamp":1567868572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-7328","authenticated-orcid":false,"given":"Justin C.","family":"Tossey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-2360","authenticated-orcid":false,"given":"Joshua","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-5649","authenticated-orcid":false,"given":"Jeffrey B.","family":"VanDeusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-8492","authenticated-orcid":false,"given":"Anne M.","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7581-1471","authenticated-orcid":false,"given":"Kyle","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-123X","authenticated-orcid":false,"given":"Matthew J.","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"issue":"1","key":"1309_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"1309_CR2","first-page":"2140","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(22):2140\u20131.","journal-title":"N Engl J Med"},{"issue":"19","key":"1309_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"18","key":"1309_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"key":"1309_CR5","unstructured":"Onivyde (irinotecan liposome) [package insert]. Basking Ridge: Ipsen Biopharmaceuticals, Inc.; 2017."},{"issue":"10018","key":"1309_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"issue":"32","key":"1309_CR7","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914\u201320.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1309_CR8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1309_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/COC.0b013e3181b4e3b0","volume":"33","author":"V Gebbia","year":"2010","unstructured":"Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G. Irinotecan plus bolus\/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol. 2010;33(5):461\u20134.","journal-title":"Am J Clin Oncol"},{"issue":"33","key":"1309_CR10","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.3748\/wjg.v18.i33.4533","volume":"18","author":"C Neuzillet","year":"2012","unstructured":"Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefevre L, Bonnetain F, et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol. 2012;18(33):4533\u201341.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1309_CR11","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","volume":"101","author":"C Yoo","year":"2009","unstructured":"Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101(10):1658\u201363.","journal-title":"Br J Cancer."},{"issue":"6","key":"1309_CR12","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00280-012-1875-1","volume":"69","author":"A Zaniboni","year":"2012","unstructured":"Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012;69(6):1641\u20135.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"1309_CR13","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","volume":"74","author":"AV Kalra","year":"2014","unstructured":"Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74(23):7003\u201313.","journal-title":"Cancer Res"},{"issue":"5","key":"1309_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12032-016-0762-8","volume":"33","author":"DA Goldstein","year":"2016","unstructured":"Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, Bekaii-Saab T, Noonan AM. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Med Oncol. 2016;33(5):48.","journal-title":"Med Oncol"},{"key":"1309_CR15","unstructured":"ASP drug pricing files. Centers for Medicare and Medicaid Services. \n                    https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice\/2019ASPFiles.html\n                    \n                  . Accessed 10 Apr 2019."},{"key":"1309_CR16","first-page":"1","volume":"122","author":"CD Fryar","year":"2018","unstructured":"Fryar CD, Kruszon-Moran D, Gu Q, Ogden CL. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999\u20132000 through 2015\u20132016. Natl Health Stat Rep. 2018;122:1\u201316.","journal-title":"Natl Health Stat Rep"},{"issue":"2","key":"1309_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1586\/14737167.5.2.153","volume":"5","author":"JW Tumeh","year":"2005","unstructured":"Tumeh JW, Moore SG, Shapiro R, Flowers CR. Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2005;5(2):153\u201362.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1309_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78\u201387.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1309_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-018-4605-1","volume":"18","author":"DC Glassman","year":"2018","unstructured":"Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, et al. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer. 2018;18(1):693.","journal-title":"BMC Cancer"},{"issue":"2","key":"1309_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1758834016676011","volume":"9","author":"DH Ahn","year":"2017","unstructured":"Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, et al. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017;9(2):75\u201382.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"1309_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40273-017-0592-3","volume":"36","author":"N Fleeman","year":"2018","unstructured":"Fleeman N, Abdulla A, Bagust A, Beale S, Richardson M, Stainthorpe A, et al. Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(3):289\u201399.","journal-title":"Pharmacoeconomics"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1309-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-019-1309-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1309-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T00:45:37Z","timestamp":1599353137000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-019-1309-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1309"],"URL":"https:\/\/doi.org\/10.1007\/s12032-019-1309-6","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anne Noonan served as a paid member of the Data Safety Monitoring Board for Helsinn in 2015\u20132016 and a paid advisory board member for QED Therapeutics and Exelixis in 2019. No other authors have any potential conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"87"}}